Glen Goss

533 total citations
19 papers, 416 citations indexed

About

Glen Goss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Glen Goss has authored 19 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Glen Goss's work include Lung Cancer Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (3 papers). Glen Goss is often cited by papers focused on Lung Cancer Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (3 papers). Glen Goss collaborates with scholars based in Canada, United States and Australia. Glen Goss's co-authors include Yvon Cormier, Richard Gregg, Joseph Ayoub, David J. Stewart, D. C. T. Wong, A. Muldal, E. Eisenhauer, Ming‐Sound Tsao, William K. Evans and Garth Nicholas and has published in prestigious journals such as Journal of Clinical Oncology, CHEST Journal and Annals of Oncology.

In The Last Decade

Glen Goss

19 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Glen Goss Canada 11 294 174 138 128 43 19 416
Shiven B. Patel United States 12 276 0.9× 168 1.0× 106 0.8× 36 0.3× 46 1.1× 47 420
Nils P. Boye Norway 6 342 1.2× 180 1.0× 137 1.0× 296 2.3× 26 0.6× 7 460
Yeun Mi Yim United States 11 270 0.9× 139 0.8× 68 0.5× 76 0.6× 29 0.7× 27 427
Van Echo Da United States 9 290 1.0× 138 0.8× 116 0.8× 177 1.4× 35 0.8× 18 393
Samer Tabchi Lebanon 12 214 0.7× 141 0.8× 66 0.5× 18 0.1× 23 0.5× 24 326
A. Gottlieb United States 9 231 0.8× 74 0.4× 109 0.8× 71 0.6× 101 2.3× 11 451
Malinda Itchins Australia 12 285 1.0× 202 1.2× 67 0.5× 73 0.6× 28 0.7× 45 411
Joel Saltzman United States 12 230 0.8× 93 0.5× 124 0.9× 23 0.2× 46 1.1× 34 395
M.C. Pennucci Italy 9 287 1.0× 355 2.0× 93 0.7× 20 0.2× 41 1.0× 17 504
Kyung‐Hun Lee South Korea 11 205 0.7× 73 0.4× 143 1.0× 28 0.2× 17 0.4× 20 360

Countries citing papers authored by Glen Goss

Since Specialization
Citations

This map shows the geographic impact of Glen Goss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glen Goss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glen Goss more than expected).

Fields of papers citing papers by Glen Goss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glen Goss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glen Goss. The network helps show where Glen Goss may publish in the future.

Co-authorship network of co-authors of Glen Goss

This figure shows the co-authorship network connecting the top 25 collaborators of Glen Goss. A scholar is included among the top collaborators of Glen Goss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glen Goss. Glen Goss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Turner, Jane, Gregory R. Pond, Alain Tremblay, et al.. (2021). Risk Perception Among a Lung Cancer Screening Population. CHEST Journal. 160(2). 718–730. 16 indexed citations
2.
Goffin, John R., Gregory R. Pond, Serge Puksa, et al.. (2020). Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. BMC Pulmonary Medicine. 20(1). 300–300. 13 indexed citations
3.
Pond, Gregory R., Alain Tremblay, Michael Johnston, et al.. (2020). Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. Clinical Trials. 17(2). 202–211. 2 indexed citations
4.
Taghizadeh, Niloofar, Alain Tremblay, Sonya Cressman, et al.. (2019). Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. BMJ Open. 9(1). e024719–e024719. 38 indexed citations
5.
Yang, James Chih‐Hsin, Glen Goss, Enriqueta Felip, et al.. (2017). LUX-Lung 8 phase III trial: Analysis of long-term response to second-line afatinib in patients with advanced squamous cell carcinoma (SCC) of the lung. Annals of Oncology. 28. ii37–ii37. 3 indexed citations
6.
McGee, Sharon F., Tinghua Zhang, Scott A. Laurie, et al.. (2017). The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small-cell Lung Cancer. Clinical Lung Cancer. 19(1). e91–e99. 22 indexed citations
7.
Goss, Glen, Ian Lorimer, Ming‐Sound Tsao, et al.. (2010). A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.. Journal of Clinical Oncology. 28(18_suppl). LBA7005–LBA7005. 58 indexed citations
8.
9.
Butts, Charles, H Anderson, Andrew W. Maksymiuk, et al.. (2009). Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 3055–3055. 13 indexed citations
10.
11.
12.
Murray, Nevin, Charles Butts, Andrew W. Maksymiuk, et al.. (2005). A liposomal MUC1 vaccine for treatment of non-small cell lung cancer (NSCLC): Updated survival results from patients with stage IIIB disease. Journal of Clinical Oncology. 23(16_suppl). 7037–7037. 6 indexed citations
13.
Ludwig, Heinz, Clifford A. Hudis, Glen Goss, & Brian Leyland‐Jones. (2004). Epoetin Alfa: Future Directions and Future Research. The Oncologist. 9(S5). 70–73. 1 indexed citations
14.
Goss, Glen, et al.. (1998). Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.. PubMed. 2(1). 32–9. 7 indexed citations
15.
Evans, William K., et al.. (1995). Oral Etoposide and Carboplatin. American Journal of Clinical Oncology. 18(2). 149–155. 51 indexed citations
16.
Cormier, Yvon, E. Eisenhauer, A. Muldal, et al.. (1994). Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Annals of Oncology. 5(3). 283–285. 123 indexed citations
17.
Vincent, Mark, Glen Goss, Clive Sinoff, et al.. (1994). Bi-weekly vincristine, epirubicin and methylprednisolone in alkylator-refractory multiple myeloma. Cancer Chemotherapy and Pharmacology. 34(4). 356–360. 2 indexed citations
18.
Gore, Martin, R Powles, A. Lakhani, et al.. (1989). Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemotherapy and Pharmacology. 23(6). 373–376. 28 indexed citations
19.
Powles, R, et al.. (1985). Prevention of graft versus host disease following allogeneic bone marrow transplantation.. PubMed. 10(2-3). 133–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shiven B. Patel Breakdown of academic impact, for papers by Nils P. Boye Breakdown of academic impact, for papers by Yeun Mi Yim Breakdown of academic impact, for papers by Van Echo Da Breakdown of academic impact, for papers by Samer Tabchi Breakdown of academic impact, for papers by A. Gottlieb Breakdown of academic impact, for papers by Malinda Itchins Breakdown of academic impact, for papers by Joel Saltzman Breakdown of academic impact, for papers by M.C. Pennucci Breakdown of academic impact, for papers by Kyung‐Hun Lee
Rankless by CCL
2026